Other than ibrutinib, clients with M-CLL, devoid of TP53 aberrations and in good shape enough to tolerate FCR therapy, should be very good candidates with the latter, with the benefit becoming that this treatment can be completed in six months while ibrutinib need to be taken indefinitely. This selection can be especially valuable for non-compliant… Read More